Table 1.
Clinical characteristics of patients with monomorphic epitheliotropic intestinal T-cell lymphoma.
| Characteristics | Values |
|---|---|
| Age (years), median (range) | 59 (37–79) |
| Age >60 | 12 (34.3%) |
| Sex | |
| Male/Female | 22 (62.9%)/13 (37.1%) |
| Present symptoms | |
| Abdominal pain | 23 (65.7%) |
| Weight loss | 12 (34.3%) |
| Anorexia | 10 (28.6%) |
| Bowel distension | 9 (25.7%) |
| Diarrhea | 6 (17.1%) |
| Gastrointestinal bleeding | 2 (5.7%) |
| Incidental findings without symptoms | 3 (8.6%) |
| Site of involvement | |
| Small bowel alone | 23 (65.7%) |
| Small and large bowels | 5 (14.3%) |
| Large bowel alone | 4 (11.4%) |
| Gastro-duodenum | 3 (8.6%) |
| B-symptom* | 18 (51.4%) |
| Acute event at presentation | |
| Bowel perforation/Bowel obstruction | 21 (60.0%)/6 (17.1%) |
| Surgical/Endoscopic diagnosis | 30 (85.7%)/5 (14.3%) |
| Performance status | |
| 0–1/2/3–4 | 25 (71.4%)/7 (20.0%)/3 (8.6%) |
| Lactate dehydrogenase (IU/L), median (range) | 330.0 (126.0–926.0) |
| Normal | 21 (60.0%) |
| Elevated | 14 (40.0%) |
| Bone marrow involvement | |
| No | 26 (74.3%) |
| Yes | 9 (25.7%) |
| Lugano stage | |
| Localized stage | 6 (17.1%) |
| Stage I | 5 (14.3%) |
| Stage II1 (local nodal involvement, para-intestinal) | 1 (2.9%) |
| Advanced stage | 29 (82.9%) |
| Stage II2 (distant nodal involvement, intra-abdomen) | 8 (22.9%) |
| Stage II2E (adjacent organ involvement) | 1 (2.9%) |
| Stage IV | 20 (57.1%) |
| IPI score | |
| Low risk | 13 (37.1%) |
| Low-intermediate risk | 13 (37.1%) |
| High-intermediate risk | 8 (22.9%) |
| High risk | 1 (2.9%) |
| PIT score | |
| Low risk | 8 (22.9%) |
| Low-intermediate risk | 13 (37.1%) |
| High-intermediate risk | 10 (28.6%) |
| High risk | 4 (11.4%) |
IPI, International Prognostic Index; PIT, Prognostic Index for T-cell lymphoma
*B-symptoms were defined as having at least one of the following symptoms: high fever, weight loss of 10% or more within the past 6 months, and night sweats.